Tuberc Respir Dis > Volume 19(2); 1972 > Article
Tuberculosis and Respiratory Diseases 1972;19(2):35-38.
DOI: https://doi.org/10.4046/trd.1972.19.2.35    Published online June 1, 1972.
The Clinical Effect of Rifampicin for Retreatment Cases for Pulmonary Tuberculosis
Sung Sook Ham, Hyung Duk Kim, Won Young Lee, Ki Ho Kim
Department of Internal Medicine, College of Medicine Yonsei University, Seoul, Korea
재치료 폐결핵환자에 대한 Rifampicin의 임상적 효과
함성숙, 김형덕, 이원영, 김기호
Abstract
The authors analyzed the clinical benefits and toxic effects of Rifampicin in 32 patients with prolonged previous chemotherapy wíthout effect (5cases were post-operative). The Rifampicin was given with one or more other anti-Tb. drugs for 3 to 12 months. The doses were 450-600mg once daily or biweekly. Sputum conversion: 14 patients had positive sputum on the begining and 7 patients (50%) became nagative with Rifampicin treatment. X-ray improvement: There was no remarkable change noticed except slight improvement in 7 cases. Symptomatic improvement: Majority of cases showed a decrease of cough and sputm sense of wellbeing, soon after the administration of Rifampicin and also showed some gain of bodyweight. Side effects: There was no serious side effect and serious liver function disturbance detected but one case had chill, fever and general bodyache and another case complained of general bodyache 6 to 7 months after the Rifampicin treatment.


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next